TL;DR: Peptides are short chains of 2 to 50 amino acids. Some, such as GLP-1 agonists or teriparatide, are approved as medicines in the EU/US. Others like BPC-157, TB-500 or epithalon are sold as “research chemicals” and are not approved for human use. Applying them in humans falls into a legal grey zone. Medical supervision is mandatory. Self-experimentation carries real legal and clinical risks.
This article does not replace medical advice. Peptides are a medically and legally sensitive topic. Many therapeutic peptides are not approved as medicines in the EU. Their use, import and possession can be legally problematic. Clarify any peptide use with a physician first.
What Peptides Actually Are
Peptides are short amino acid chains. Two to 50 amino acids, linked by peptide bonds. Anything longer is called a protein. The cutoff is arbitrary but practical: short chains behave differently than long ones. They cross membranes more easily, bind to specific receptors and act quickly.
Your body produces peptides constantly. Insulin from the pancreas regulates blood sugar. Oxytocin from the pituitary drives bonding, labor and milk ejection. Glucagon raises blood sugar when it drops. ACTH, growth hormone, ghrelin, leptin, vasopressin — all are peptides or peptide hormones.
The distinction matters: endogenous peptides have decades of research, well-characterized receptors and clear dose-response curves. Synthetic therapeutic peptides mimic these mechanisms or engage adjacent pathways. Some are approved medicines. Many are not.
For an overview of how these markers fit into your overall health, start with the guide to understanding blood values.
Approved vs. Unapproved Peptides
Regulatory status decides everything: availability, quality control, medical prescription, liability. The table below summarizes the most discussed groups.
| Peptide | EU approval status | Indication | Administration |
|---|---|---|---|
| Semaglutide (Ozempic, Wegovy) | approved | Type 2 diabetes, obesity | subcutaneous weekly |
| Liraglutide (Victoza, Saxenda) | approved | Type 2 diabetes, obesity | subcutaneous daily |
| Teriparatide (Forsteo) | approved | severe osteoporosis | subcutaneous daily |
| Desmopressin (Minirin) | approved | diabetes insipidus, enuresis | nasal/oral |
| BPC-157 | not approved | regeneration, gut (research) | research chemical |
| TB-500 (thymosin-β4) | not approved | wound healing (research) | research chemical |
| GHK-Cu | not approved (some cosmetic use) | skin, collagen | topical/subcutaneous |
| Epithalon | not approved | anti-aging (research) | research chemical |
| Selank, Semax | not approved | cognition, anxiety (research) | nasal |
| Thymosin-α1 (Zadaxin) | approved in some countries, not EU | immune modulation | subcutaneous |
| Melanotan II | not approved | skin tanning | research chemical |
Approved peptides pass through Phase 1 to 3 studies with thousands of subjects, standardized manufacturing and regulatory oversight. Unapproved peptides have not completed this process. That does not automatically mean they are useless or harmful. It means solid human data on efficacy, safety and dosing are missing.
How Peptides Work
Peptides bind to specific receptors on cell surfaces and trigger downstream signaling. Three principles explain most mechanisms.
Receptor agonism. The peptide activates a receptor the way an endogenous signaling molecule would. GLP-1 agonists mimic the intestinal hormone GLP-1 and bind to the GLP-1 receptor in pancreas and brain. They lower blood sugar, slow gastric emptying and reduce appetite.
Tissue specificity. Some peptides preferentially act at specific sites. BPC-157 (Body Protection Compound, isolated from human gastric juice) shows high affinity for tendon, muscle and gut tissue in animal models. GHK-Cu binds to collagen-producing fibroblasts in skin.
Pathway modulation. Peptides can influence several downstream pathways in parallel. Thymosin-α1 modulates T-cell maturation and strengthens innate immunity. Selank affects GABA and serotonin signaling in the brain.
The practical catch: most BPC-157, TB-500 or epithalon data come from rat and cell culture studies. Human trials are rare, small and often methodologically weak. When a vendor advertises “clinically proven”, look critically at the cited study.
Areas of Interest (research landscape, not recommendation)
The following areas are discussed in the peptide community. Important: these are theoretical application fields based on preclinical data, not proven indications. None of these uses — outside approved indications — has a lawful pathway in the EU without medical prescription.
Regeneration and wound healing. BPC-157 and TB-500 are discussed for tendon, ligament and muscle injuries. Animal data suggest accelerated healing, human data are sparse.
Metabolism and weight. GLP-1 agonists are approved and well documented here. Semaglutide leads to 10 to 15 percent weight reduction over 68 weeks in trials. The starting dose is 0.25 mg subcutaneously weekly, titrated up to 2.4 mg — under medical supervision.
Immune modulation. Thymosin-α1 is used in some countries for immunodeficiency. Zadaxin is not regularly approved in the EU. The evidence is mixed.
Cognition and stress. Selank and semax are discussed as nootropics. Russian research literature shows anxiolytic effects; Western human data remain scarce.
Anti-aging and skin. GHK-Cu is established in topical cosmetics and supports collagen. Subcutaneous use is not approved. Epithalon is promoted for telomerase activation, with thin evidence.
Growth hormone axis. CJC-1295 and ipamorelin aim to stimulate endogenous growth hormone release. Not approved, limited human data.
Across all these areas: before considering any peptide, you need clean diagnostics. Start with a structured biomarker baseline.
Routes of Administration
Peptides are proteins. The stomach digests them like any other protein. That is why injection remains the default.
Subcutaneous. The most common form. A fine insulin needle delivers the peptide into fatty tissue on the abdomen or thigh. Bioavailability 60 to 90 percent. Technically simple but not harmless: unsterile handling, wrong dosing or contaminated material can cause infections and abscesses.
Intramuscular. Deeper into muscle tissue. Longer needle, slightly higher bioavailability for some peptides, but more painful and involved. Rare in the research-chemical scene.
Nasal. Selank, semax and oxytocin are available as nasal sprays. The mucosa allows direct uptake into the bloodstream, bypassing the stomach. Bioavailability varies widely, often 5 to 20 percent.
Transdermal and topical. GHK-Cu in creams. Acts locally, systemic uptake is low. Established for skin and collagen, unsuitable for systemic effects.
Oral. Most peptides are unusable orally because acid and peptidases degrade them. Oral semaglutide (Rybelsus) uses a carrier molecule (SNAC) to cross the stomach barrier, with roughly 1 percent bioavailability.
The risk grows with the do-it-yourself factor. Whoever reconstitutes powder in sterile water, doses and injects needs aseptic technique and precise calculations. That is a task for medically trained people — not YouTube tutorials.
Legal Status: EU, US, Sports
The regulatory frame is possibly the most important point of this guide. It decides whether you receive an approved medicine from a pharmacist or a product from a grey zone.
EU. Only approved medicines may be marketed and prescribed as such. BPC-157, TB-500, epithalon, selank, semax, melanotan and subcutaneous GHK-Cu are not approved. Vendors label them as “research chemicals” — for laboratory research only, not for human use. Importing small quantities for personal use sits in a legal grey zone. Larger amounts or resale can be prosecuted as unlicensed medicinal product trade.
US. In 2023 the FDA placed several popular peptides (BPC-157, CJC-1295, ipamorelin) on Category 2 of the compounding list. This means compounding pharmacies may no longer dispense them to patients. Grey-market sales as “research chemicals” continue but are legally constrained.
Sport. Many peptides are on the WADA prohibited list. GLP-1 agonists, growth hormone secretagogues (CJC-1295, ipamorelin), thymosin-β4 and BPC-157 are banned for competitive athletes. Positive tests trigger multi-year suspensions.
The consequence for you: without a physician’s prescription for an approved preparation, you operate in legally uncertain territory. A properly issued private prescription through a physician specialized in peptide medicine is the only lawful path for approved substances.
Baseline Labs Before Peptide Use
If you are considering medically supervised peptide therapy, you need a solid baseline. Without these reference values you cannot later judge whether a change is caused by the peptide or existed before.
| Marker | Why it matters | Reference |
|---|---|---|
| ALT, AST, GGT | liver function, drug metabolism | see liver values |
| Creatinine, eGFR, urea | kidney clearance, safety | see kidney values |
| Complete blood count | inflammation, infection, marrow | basic panel |
| CRP, ESR | inflammatory baseline | CRP below 3 mg/l |
| HbA1c, fasting glucose | metabolic state, GLP-1 relevance | HbA1c below 5.7 % |
| TSH, fT3, fT4 | thyroid function | TSH 0.4–2.5 mIU/l |
| Testosterone, estradiol | hormonal baseline | age-/sex-dependent |
| IGF-1 | growth hormone peptide relevance | age-dependent |
| Lipid panel | cardiovascular risk | LDL, HDL, triglycerides |
Document this baseline before the first contact with the substance. Repeat the panel after 8 to 12 weeks. Deviations, especially in liver and kidney values, are a signal to stop and clarify medically.
Quality Criteria for Reputable Sources
If medically supervised use is on the table and the prescribed peptide is not available through a regular pharmacy, strict quality criteria apply. These criteria do not replace approval but they minimize risk.
Certificate of Analysis (COA). Independent lab certificate with HPLC purity, mass spectrometry identity and endotoxin test. Purity above 98 percent, endotoxin below 10 EU/mg. No COA: keep looking.
GMP or ISO certification. Good Manufacturing Practice is the pharmaceutical standard. ISO 9001 is the minimum for quality assurance. Both verifiable via certificate numbers.
Sterility. Injectable peptides must be sterile and pyrogen-free. Lyophilized powder in glass vials with rubber septum is standard. Loose powder bags are a deal-breaker.
Chain of custody. Cold chain from production to delivery. Peptides are heat-sensitive. Unrefrigerated transport over weeks destroys activity.
Independent testing. Third parties such as Janoshik Analytical test research-chemical-scene peptides. Results are sobering: a relevant share of tested products contains less active ingredient than labeled or shows contamination.
Risks and Open Questions
Evidence for most unapproved peptides is thin. Six points should concern you if you consider using them without medical supervision.
Lack of long-term studies. For BPC-157, TB-500, epithalon and others there are no human studies beyond 12 months. What happens at 5 or 10 years is unknown. Peptides interfere with cell growth and receptor signaling — time horizons matter.
Tumor growth. Growth-promoting peptides (GHK-Cu, BPC-157, growth hormone peptides) could theoretically accelerate existing tumors. Preclinical data are mixed, clinical relevance is unclear. With a cancer history: absolute contraindication.
Immune reactions. Synthetic peptides can trigger antibody responses. This weakens the effect and can cause allergic or autoimmune reactions.
Injection risks. Abscesses, infections, granulomas, lipohypertrophy at the injection site. Unsterile work dramatically increases risk.
Quality problems. Contamination with bacterial endotoxins, heavy metals or incorrectly synthesized side peptides. Without COA and GMP there is no quality guarantee.
Legal consequences. Unprescribed import, possession in larger quantities and resale can trigger customs and pharmaceutical law consequences.
Anyone who uses peptides despite these risks does so at their own risk and should at minimum secure medical supervision and regular biomarker tracking.
Ethics and the Biohacker Community
The peptide community is split. On one side are medical users with a prescription — mostly GLP-1 agonists for obesity or teriparatide for osteoporosis. On the other side are biohackers who inject BPC-157 after sports injuries or epithalon for anti-aging on their own.
Both groups have legitimate interests but very different risk profiles. The medical path offers quality control, dose safety and liability. The biohacker path offers access to substances not medically available — at the cost of missing safety nets.
The ethics are individual. Someone informed and cautious who works with baseline data acts differently from someone injecting a powder from the internet based on rumor. But even the informed biohacker stays in the grey zone and carries the full risk.
A sober piece of advice: if you are considering peptides, start with approved substances that match a genuine medical indication for you. GLP-1 for obesity, teriparatide for osteoporosis. Everything else requires an honest weighing of risk, benefit and legal situation — together with a physician, not alone.
Peptides in Context With Other Approaches
Peptides are not a standalone fix. They deliver value only in the context of sleep, nutrition, training and recovery. Three connections are particularly relevant.
Peptides and base labs. Without solid liver and kidney values, no peptide use. Start with the guides to liver values and kidney values.
Peptides and supplements. GHK-Cu is sometimes combined with collagen peptides. Antioxidants like NAC and omega-3 support the liver during metabolically active substances. A structured entry point: supplement beginners guide.
Peptides and behavior change. GLP-1 agonists work best with calorie reduction and movement. Without accompanying behavior change, weight loss often returns after stopping.
Conclusion: Between Medicine and Grey Zone
Peptides are among the most interesting substance classes of the coming years. GLP-1 agonists have reshaped obesity medicine. Teriparatide offers new options for severe osteoporosis. At the same time, a grey market for research chemicals is growing — legally, medically and ethically problematic.
Three steps to start:
- Diagnostics before action. A clean baseline with liver, kidney, blood count and hormone values is the foundation of any consideration.
- Through the physician only. Approved peptides come by prescription. Everything else sits in the grey zone.
- Document. Trend tracking over 12 months says more than any single measurement.
Start today with the biomarker baseline checklist and document everything digitally. Check out the features of Lab2go or compare the plans and pricing if you want to go deeper.
This article does not replace medical advice. Peptides act on central signaling pathways. In the EU, many therapeutic peptides are not approved as medicines and human use sits in a legal grey zone. Discuss any peptide use with a physician. Self-medication is legally and medically risky.
Article FAQ
- What are peptides in simple terms?
- Peptides are short chains of 2 to 50 amino acids. They are shorter than proteins, which contain more than 50. Endogenous peptides like insulin, oxytocin and glucagon control core processes such as blood sugar, labor contractions and hunger. Therapeutic peptides are produced synthetically and aim to engage similar receptors.
- Are BPC-157 and TB-500 legal in the EU and US?
- In the EU, BPC-157, TB-500, epithalon, GHK-Cu, selank and semax are not approved as medicines. They are sold as 'research chemicals' labeled 'not for human use'. Using them on humans is therefore legally problematic. In the US the FDA moved BPC-157 and several others to Category 2 in 2023, which restricts compounding pharmacies from dispensing them.
- Which peptides are approved?
- GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) are approved for type 2 diabetes and obesity. Teriparatide (Forsteo) is used for severe osteoporosis. Desmopressin treats diabetes insipidus. Approval makes the crucial difference between a medicine and a research chemical.
- How are peptides administered?
- Most peptides are injected subcutaneously into fatty tissue because oral intake exposes them to digestion in the stomach. Oral bioavailability is usually below 1 percent. Alternatives include nasal sprays (selank, semax), transdermal creams (GHK-Cu) and intramuscular injections. Subcutaneous remains the standard.
- Which blood values matter before peptide use?
- Before any peptide application, check liver values (ALT, AST, GGT), kidney markers (creatinine, eGFR), complete blood count, inflammation markers (CRP) and baseline hormones (TSH, testosterone or estradiol, IGF-1). This baseline shows whether organ function is intact and provides a reference point for follow-up. Without a baseline you lose the ability to interpret later changes.
- What does 'research use only' mean on peptide vendor sites?
- 'Research use only' is a legal disclaimer used by vendors. It signals that the product is not approved as a medicine and is not intended for human use. In practice, a large share of these peptides are bought by individuals for self-experimentation. The disclaimer shifts legal responsibility to the buyer but does not prevent misuse.
- How do you identify a reputable peptide source?
- Reputable sources provide a Certificate of Analysis (COA) with purity, identity and endotoxin data, hold GMP or ISO certification and produce sterile product. Purity should exceed 98 percent, endotoxin stay below 10 EU/mg. Even with all that, application without medical supervision remains legally and medically problematic. Quality is not a substitute for approval.
- What are the biggest peptide risks?
- Three risks dominate. First, the lack of long-term human studies. Most data come from animal models or small pilot trials. Second, quality issues in grey-market products, including bacterial contamination and heavy metals. Third, incorrect dosing because injection often happens without clinical oversight. On top of that come legal risks related to import and possession.
- Can peptides be taken orally?
- Most peptides are broken down in the stomach by peptidases before they can act. BPC-157 oral bioavailability is reported as low and solid human data are missing. Semaglutide is available as a tablet (Rybelsus) with a carrier formulation that achieves around 1 percent bioavailability. For most therapeutic peptides, injection stays the standard.
- Do peptides replace conventional medicine?
- No. Approved peptides like GLP-1 agonists complement or replace other diabetes and obesity medications in specific cases, but only under medical supervision. Unapproved peptides are not medicines and do not replace established therapy. If you have pain, wounds or inflammation, you need proper diagnostics, not a self-experiment with research chemicals.
Discussion
Community comments coming soon. Until then, we welcome feedback and questions via email.
E-Mail anzeigen
